Description
Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be Shared at EADV
MORE INFORMATION:
https://www.businesswire.com/news/home/20260723966929/en/Envedas-Positive-Phase-1B-Results-for-ENV-294-a-Potential-First-in-Class-Oral-Therapy-for-Moderate-to-Severe-Atopic-Dermatitis-Were-Presented-at-AAD-Innovation-Academy-Additional-Details-to-Be-Shared-at-EADV